DCLK1-IN-1 is a potent and selective inhibitor of doublecortin-like kinase 1 (DCLK1), a protein implicated in the regulation of tumor stemness and cancer progression. It is primarily used in cancer research to target tumor-initiating cells, especially in models of colorectal, pancreatic, and liver cancers. By inhibiting DCLK1, this compound demonstrates anti-tumor and anti-metastatic effects, including suppression of cell proliferation, induction of apoptosis, and reduction of cancer stem cell populations. It also shows potential in disrupting epithelial-mesenchymal transition (EMT), a key process in cancer metastasis. Due to its ability to modulate signaling pathways such as Wnt/β-catenin and Notch, DCLK1-IN-1 serves as a valuable tool for studying oncogenic signaling and developing targeted cancer therapies.